Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Buy rating and announces Price Target of $15.
Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Buy rating and announces Price Target of $15.